ArticleChinese journal of integrative medicine2026
Isoquercitrin Improves Insulin Resistance by Inhibiting PTP1B-Regulated IRS/PI3K/AKT Signaling Pathway.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting Protein Tyrosine Phosphatase 1B: Recent Advances in Natural, Synthetic, and Multitarget Inhibitors for Diabetes Therapy.Biomolecules · 2026Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the molecular mechanism by which protein tyrosine phosphatase 1B (PTP1B) enzyme regulates insulin resistance (IR) in diabetes mellitus, and the regulation of isoquercitrin (IS) on PTP1B in vitro and in vivo.
methodsIn vitro, PTP1B overexpression plasmid was constructed and transiently transfected into human hepatocellular liver carcinoma (HepG2) cells. A co-inducer was prepared by mixing a 0.125 mmol/L palmitic acid solution with a 1.0 × 10
resultsIn both in vivo and in vitro experiments, IS significantly improved IR, reduced levels of blood glucose, total cholesterol, triglycerides, and other metabolic indicators in mice, effectively controlled body weight, and restored pancreatic cell morphology (P<0.05 or P<0.01). At the genomic level, IS improved the expressions of related factors in the IRS/PI3K/AKT signaling pathway by regulating the expression of PTP1B (P<0.05 or P<0.01), thereby maintaining the homeostasis of the pathway.
conclusionIS can improve IR by inhibiting the IRS/PI3K/AKT signaling pathway through PTP1B intervention.
Indexed as
Identifiers
41199094What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.